Intimation of Annual Report and AGM Notice 2020
Total Page:16
File Type:pdf, Size:1020Kb
Ref: MHL/Sec&Legal/2021-22/29 Date: July 18, 2021 To, Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block, Dalal Street, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS Sub: Copy of Annual Report of the Company for the Financial Year 2020-2021 along with the Notice convening the 21st Annual General Meeting Ref: Our earlier letter dated July 05, 2021 having reference no. MHL/Sec&Legal/2021-22/23 Dear Sir/Madam, With reference to the captioned subject, our earlier letter dated July 05, 2021 having reference no. MHL/Sec&Legal/2021-22/23 wherein we had informed the Exchange about the 21st Annual General Meeting (‘AGM’) of the Company. In continuation to the same and as required under Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Annual Report of the Company for the Financial Year 2020-2021 along with the Notice convening the 21st AGM of the Company scheduled to be held on Wednesday, August 11, 2021 at 9.30 A.M. (IST) through Video Conferencing / Other Audio Visual Means (‘VC / OAVM’) in compliance with the General Circular No. May 05, 2020 read with Circulars dated April 08,2020, April 13, 2020 and January 13, 2021 issued by the Ministry Corporate Affairs and Circular dated May 12,2020 and January 15, 2021 issued by the Securities and Exchange Board of India. The Annual Report of the Company for the Financial Year 2020-21 and the Notice convening the 21st AGM of the Company are available on the website of the Company at www.metropolisindia.com and are also being dispatched to all the eligible shareholders whose email ID’s are registered with the Company / Depository(ies). You are requested to take above information on record. Thanking You, Yours Faithfully, For Metropolis Healthcare Limited Danish Allana Interim Compliance Officer Membership No. A61517 BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. Metropolis Healthcare Limited | BREAK Annual Report 2020-21 THE CHAIN Registered Office: 250-D, Udyog Bhavan, Hind Cycle Marg, Behind Glaxo, Worli, Mumbai – 400030 Customer Care: 022-33993939 ANNUAL REPORT 202 0 -21 Our Approach to Reporting ABOUT THIS REPORT This Report is aligned with the International Integrated Reporting Council’s (IIRC) globally accepted framework. Through this document, Metropolis Healthcare Limited (‘Metropolis’ or ‘the Company’) aims Across the Pages to strengthen its communication with the stakeholders with respect to material activities, value creation process, business highlights and future prospects. This Report follows and adopts guidelines, as laid out by SEBI with respect to Annual Report. 01-31 32-97 98-236 CORPORATE STATUTORY FINANCIAL SCOPE AND BOUNDARY OVERVIEW REPORTS STATEMENTS This Annual Report comprises all the relevant aspects of operations of Metropolis. It also consists of the desired statutory disclosures and 02 20 32 98 audited annual financial statements for the year ended 31 March BREAK THE HUMAN MANAGEMENT STANDALONE CHAIN CAPITAL DISCUSSION 2021. All the subsidiaries are included in the consolidated financial AND ANALYSIS information. 166 FRAMEWORKS 04 22 CONSOLIDATED HIGHLIGHTS SOCIAL AND OF THE YEAR RELATIONSHIP 37 The content and structure of this Annual Report is guided by the BOARD’S CAPITAL framework endorsed by the Integrated Reporting <IR> Council. REPORT Besides, the Company fully complies with the NSE and BSE listings as 06 24 well SEBI Compliances. It is committed to embracing best practices in METROPOLIS NATURAL reporting to ensure transparency and better stakeholder engagement. AT A GLANCE CAPITAL 65 237 ASSURANCE CORPORATE NOTICE GOVERNANCE 08 26 REPORT Metropolis’ Board of Directors and its subcommittees have reviewed CHAIRMAN’S BOARD OF the Report and satisfied themselves on the materiality, accuracy, MESSAGE DIRECTORS and balance of disclosures in this Report. The Board has not sought 91 independent assurance of the Report, other than for the annual BUSINESS financial statements. 10 29 RESPONSIBILITY LETTER FROM LEADERSHIP REPORT MD’S DESK TEAM Find our online version at https://www.metropolisindia.com/ 12 30 about-metropolis/investors/ Scan to download BUSINESS AWARDS & MODEL RECOGNITION Investor Information BSE Code: 542650 NSE Symbol: METROPOLIS 14 31 Bloomberg Code: METROHL:IN FINANCIAL CORPORATE AGM Date: August 11, 2021 CAPITAL INFORMATION AGM Mode: Video Conferencing 16 Disclaimer: This document contains statements about expected future events and financials of Metropolis Healthcare Limited, which are forward-looking. By their SERVICE nature, forward-looking statements require the Company to make assumptions CAPITAL and are subject to inherent risks and uncertainties. There is significant risk that the assumptions, predictions, and other forward-looking statements may not prove to be accurate. Readers are cautioned not to place undue reliance on forward- looking statements as a number of factors could cause assumptions, actual future 18 results and events to differ materially from those expressed in the forward-looking INTELLECTUAL statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the CAPITAL Management Discussion and Analysis section of this Annual Report. CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS 2020 was all about the fight between overarching challenges and their possible solutions. A year that highlighted the power of endurance and prudence was also the year that underlined the importance of precautions, promptness, and accuracy when it came to containing the spread of the COVID-19 pandemic. The outbreak of COVID-19 reasserted the essential role of diagnostics in fighting pandemics. At a time when the world is battling a grave health crisis, if frontline warriors are the heroes, diagnostic centers are inarguably the essential support crew. At Metropolis, we understand that effective diagnostic is vital for timely responding to the outbreak. We realise the role we play in generating a roadmap for the global good. We are aware of the responsibility we must shoulder to take the world towards a safer tomorrow. WE KNOW WE ARE THE ONES WHERE THE CONCEPT OF ‘BREAK THE CHAIN’ BREAK BEGINS! AND THIS, IS OUR STORY! THE CHAIN 2 METROPOLIS HEALTHCARE LTD ANNUAL REPORT 2020-21 3 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS HIGHLIGHTS OF THE YEAR Our revenue Due to higher test volumes and value per test, COVID-19 Tests contributed a significant portion of our revenue in Q1 and Q2FY21, whereas Non-COVID business continued to rebound in Q3FY21 strongly. Covid Non-Covid contribution from Non-COVID business grew significantly year on year in Q4FY21. While the number of COVID-19 tests COVID and Non- increased in Q4FY21 but revenue contribution decreased with the Government’s decision of lower pricing. COVID business (%) Q1FY22 witnessed COVID-19 infections increasing again which was soon followed by lockdown restrictions. In the medium term, as the vaccination campaign gains traction, the Non-COVID industry is expected to thrive. Going ahead, we anticipate increased revenue from COVID-19 allied tests in FY22. FOR THE FIRST TIME, 8 LAKH NEW CUSTOMERS USED METROPOLIS FOR COVID TesTs. In H2FY21, we sAw A HeAlTHY COnVeRsIOn RATe OF 10% OF CUSTOMERS WHO TRIED METROPOLIS FOR A NON-COVID TEST. WE ANTICIPATE HIGHER CONVERSION RATES IN THE COMING QUARTERS. 29 71 34 66 QI FY21 Q2 FY21 Our Non-COVID business ` over the last year 998 Crores, up 17 % Revenue in FY21 and Percentage FY20 REVENUE Growth as Compared to FY20 Q1 FY20 203 Q2 FY20 224 Q3 FY20 224 ` 288 Crores Q4 FY20 206 EBIDTA 19 81 14 86 FY21 NON-COVID REVENUE Q3 FY21 Q4 FY21 ` 183 Crores, up 44 % Q1 FY21 102 Q2 FY21 189 PAT in FY20 and Percentage Growth as Compared to FY20 Q3 FY21 223 Q4 FY21 251 58 %, up 200 bps Percentage Revenue Share of B2C in Focus Cities ` 9.8 Million Patient Visits ` Million EBIDTA: Earnings Before Interest, 19.0 Depreciation, Taxes and Amortisation PAT: Profit after Tax Tests Conducted B2C: Business to Customers in FY2020-21 4 METROPOLIS HEALTHCARE LTD ANNUAL REPORT 2020-21 5 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS METROPOLIS One of the leading players in the Indian diagnostic space Vision Our Values To be a respected healthcare brand trusted by clinicians, Incepted in the year 1980, Metropolis is among the leading diagnostics players in India, with a dominant share in patients and stakeholders. INTEGRITY EMPATHY ACCURACY the country’s western and southern region. Metropolis offers a comprehensive range of 4,000+ clinical laboratory Positively impact lives is in our is in our is in our tests and profiles as one of the market leaders. These tests are used for prediction, early detection, diagnostic of patients in their most screening, confirmation and/or monitoring of different diseases. Additionally, the Company also offers analytical VEINS BLOOD DNA anxious times and turn their and support services to clinical research